Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rafanan, A. L.
Right arrow Articles by Schilz, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rafanan, A. L.
Right arrow Articles by Schilz, R.
(Chest. 2000;118:1497-1500.)
© 2000 American College of Chest Physicians

Progressive Portopulmonary Hypertension After Liver Transplantation Treated With Epoprostenol*

Albert Lim Rafanan, MD; Janet Maurer, MD, FCCP; Atul C. Mehta, MD, FCCP and Robert Schilz, DO, PhD, FCCP

Portopulmonary hypertension (PPHTN) is an uncommon complication of advanced liver disease. Epoprostenol has been effective in the treatment of PPHTN and has been used as a bridge to orthotopic liver transplantation (OLT). The role of OLT in the reversal of PPHTN is unclear. We report a case of severe PPHTN (mean pulmonary artery pressure of 45 mm Hg) that progressed after OLT. Acute dosing with epoprostenol improved the pulmonary vascular resistance by 55% and the cardiac index by 134%. Hemodynamic and symptomatic improvements were maintained after 18 months of long-term treatment with epoprostenol. This is the first reported case of a successful favorable outcome after treatment for progressive PPHTN after OLT. Our case report complements previous reports by highlighting the potential effective use of epoprostenol as a definitive treatment for PPHTN.

Key Words: cirrhosis • epoprostenol • liver • liver transplantation • pulmonary hypertension




This article has been cited by other articles:


Home page
 Eur Respir JHome page
R. Rodriguez-Roisin, M.J. Krowka, Ph. Herve, M.B. Fallon, and on behalf of the ERS Task Force Pulmonary-Hepatic
Pulmonary-Hepatic vascular Disorders (PHD)
Eur. Respir. J., November 1, 2004; 24(5): 861 - 880.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Minder, M. Fischler, B. Muellhaupt, M.P. Zalunardo, R. Jenni, P-A. Clavien, and R. Speich
Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension
Eur. Respir. J., October 1, 2004; 24(4): 703 - 707.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. Kotloff, V. N. Ahya, and S. W. Crawford
Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation
Am. J. Respir. Crit. Care Med., July 1, 2004; 170(1): 22 - 48.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American College of Chest Physicians.